作者：
Jaime,Monserrat Villatoro [1]
;
Gina,Mejía-Abril [2]
;
Lucía,Díaz García [1]
;
Pablo,Zubiaur [2]
;
María,Jiménez González [3]
;
Guillermo,Fernandez Jimenez [4]
;
Inés,Cancio [4]
;
José Ramón,Arribas [5]
;
Carmen,Suarez Fernández [6]
;
Jesús,Mingorance [7]
;
Julio,García Rodríguez [7]
;
José Ramón,Villagrasa Ferrer [8]
;
Antonio J,Carcas [1]
;
Jesús,Frías [1]
;
Francisco,Abad-Santos [2]
;
Alberto M,Borobia [1]
;
Elena,Ramírez [1]
;
On Behalf Of The Covid Hulp Working Group And Other Collaborators From Hospital Universitario de la Princesa
作者单位：
Clinical Pharmacology Department, La Paz University Hospital-IdiPAZ, Universidad Autónoma de Madrid, 28046 Madrid, Spain.
[1]
Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), 28006 Madrid, Spain.
[2]
Clinical Trial Unit, La Paz University Hospital-IdiPAZ, 28046 Madrid, Spain.
[3]
Medical Information Unit, Instituto de Investigación Sanitaria La Princesa (IP), Hospital Universitario de La Princesa, 28006 Madrid, Spain.
[4]
Internal Medicine Department, La Paz University Hospital-IdiPAZ, Universidad Autónoma de Madrid, 28046 Madrid, Spain.
[5]
Internal Medicine Department, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, 28006 Madrid, Spain.
[6]
Microbiology Department, La Paz University Hospital-IdiPAZ, 28046 Madrid, Spain.
[7]
Preventive Medicine Department, Hospital Universitario de La Princesa, Faculty of Medicine, Instituto de Investigación Sanitaria La Princesa (IP), Universidad Autónoma de Madrid (UAM), 28006 Madrid, Spain.
[8]
DOI
10.3390/ph15010078
PMID
35056135
发布时间
2022-01-28
换一批
换一批
